US cancer therapies demand will grow ten percent annually through 2009. Gains will be driven by more incidence and detection of cancer coupled with a range of highly effective, but expensive, new treatments. Biotechnology-based therapies hold the best prospects. Outpatient facilities will be the fastest growing market.
This study analyzes the $16.8 billion US market for cancer therapies. It presents historical US demand data (1994, 1999 and 2004) and forecasts to 2009 and 2014 by cancer type (e.g., breast, digestive system, genital system, leukemia, lymphoma); by product/procedure (e.g., chemotherapy drugs, surgery, radiation therapy, biotechnology-based drugs, hormonal therapy, vaccines, nanotechnology, stem cells); and by institution/provider (e.g., hospitals, outpatient facilities, physicians? offices, home health care).
The study also considers market environment trends and indicators, details industry composition and market share, and profiles 28 selected companies including Bristol Myers-Squibb, Merck, Pfizer, Amgen, Genentech, AstraZeneca, Roche Holding, Radiation Therapy Services, and US Oncology.